Kisqali 200 mg – Breast Cancer Treatment Kisqali (Ribociclib)

Kisqali is a modern targeted therapy used in the treatment of HR-positive / HER2-negative advanced or metastatic breast cancer. It is part of the CDK4/6 inhibitor class, which represents a major advancement in oncology care.

What is Kisqali ?

Kisqali belongs to a group of drugs called CDK4/6 inhibitors, which control cell division and growth.

In hormone-positive breast cancer, these signals become overactive, leading to uncontrolled tumor growth. Kisqali works by:

• Slowing down cancer cell division
• Reducing tumor progression
• Improving long-term disease control

In simple terms:
It helps stop cancer cells from multiplying.

Indications

Kisqali (Ribociclib) is used in:

• HR-positive breast cancer
• HER2-negative cases
• Advanced or metastatic disease
• In combination with hormonal therapy such as Letrozole or Fulvestrant

Dosage and Administration

• Common dose: 200 mg or as prescribed by the physician
• Taken orally
• Standard cycle: 21 days on treatment + 7 days off
• Should be taken at the same time every day

Common Side Effects

• Low white blood cell count (neutropenia)
• Fatigue
• Nausea
• Mild hair thinning
• Skin rash
• Rarely: heart rhythm or liver function changes

Regular monitoring is required during treatment.

Availability in Egypt

Kisqali (Ribociclib) is available in specialized oncology centers and major pharmacies in Egypt. It is a high-cost medication that requires close medical supervision.

Kisqali (Ribociclib) 200 mg is an important targeted therapy for HR-positive / HER2-negative breast cancer, helping to slow tumor growth and improve disease control in advanced stages.

Medical Disclaimer: This content is for educational purposes only and does not replace professional medical advice.